article thumbnail

J&J, AbbVie, Sanofi and many other companies face competition probe in Turkey

Fierce Pharma

Turkish authorities have launched an investigation into 19 pharmaceutical companies to probe whether their operations violated the country’s competition law, the Turkish Competition Authority discl | The companies, which include Pfizer, J&J, Sanofi, AbbVie, AstraZeneca, Merck and others are being probed for potentially violating Turkish competition (..)

article thumbnail

Innovation key for boosting UK biopharma competitiveness

European Pharmaceutical Review

New recommendations to boost the competitiveness in UK biopharma and Medtech sectors have been published by Imperial College London. The ‘Sectoral Systems of Innovation and the UK’s Competitiveness’ reports assess the value-added per capita of each sector and how they compare internationally.

article thumbnail

FTC order could ease biopharma competition

European Pharmaceutical Review

to address the potential competitive harm Amgen’s $27.8 Consolidation in the pharmaceutical industry has given companies the power and incentive to engage in exclusionary rebating practices, which can lead to sky-rocketing prices on essential medications,” stated Henry Liu, Director of the FTC’s Bureau of Competition.

article thumbnail

UK Government to fund research into new obesity treatments

Pharmaceutical Technology

The UK Government has announced funds worth $24.17m (£20m) to conduct research for developing new obesity therapies and technologies. The latest investment by the government is anticipated to aid the NHS in saving billions over time and guarantee that crucial funds are allocated to important key frontline services.

article thumbnail

Global comparator data signal “alarm bells” for UK Government, says APBI

pharmaphorum

Latest UK Life Sciences Competitive Indicators “ought to ring alarm bells across Government,” says ABPI. Richard Torbett, chief executive at the Association of the British Pharmaceutical Industry (ABPI) said Life Sciences Competitive Indicators (LSCI) data published last week “ought to ring alarm bells across Government”.

article thumbnail

Pharma sector reels as UK Government doubles VPAS payback rate on NHS drugs

Pharmaceutical Technology

Full details of the government’s 2023 VPAS payment calculation may be accessed on the UK Department of Health and Social Care (DHSC) page here. Calculations behind the jump in payback rate The government-calculated 2023 clawback level of 26.5%

article thumbnail

Innovative pharma-government partnership to enhance UK clinical trials

European Pharmaceutical Review

A major new £400 million public-private collaboration has launched in the UK, aimed at enhancing the life sciences sector’s economic growth and the competitiveness over the next five years. The post Innovative pharma-government partnership to enhance UK clinical trials appeared first on European Pharmaceutical Review.